Linaclotide (CAS 851199-59-2) Peptide Agonist for IBS-C & CIC | Alfa Chemistry Scientific Product Insight

Linaclotide (CAS 851199-59-2) is a synthetic peptide comprised of 14 amino acids and characterized by three strategically positioned disulfide bonds, giving it a cyclic and conformationally constrained structure. As a highly potent and selective agonist of the guanylate cyclase-C (GC-C) receptor, linaclotide mimics the physiological action of endogenous peptides such as guanylin and uroguanylin, which regulate intestinal fluid homeostasis and bowel function.

Figure 1. Structure of linaclotide^[1].

Unlike small-molecule APIs, linaclotide's biological action is localized mainly within the gastrointestinal lumen. Upon oral administration, it engages the GC-C receptors expressed on the apical surface of intestinal epithelial cells, triggering a cascade that increases intracellular and extracellular cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP leads to enhanced chloride and bicarbonate secretion via the cystic fibrosis transmembrane conductance regulator (CFTR) and inhibited sodium absorption—resulting in increased water influx into the intestinal lumen and accelerated intestinal transit. This unique mechanism underpins its therapeutic applications.

Figure 2. Mechanism of action of linaclotide. Linaclotide binds to the GC-Creceptor on the luminal side of intestinal epithelial cells, causing activation of the intracellular cyclic 3',5′-cGMP pathway. Subsequently, the cGMP-dependent protein kinase II (PKG II) is activated, which phosphorylates and activates the CFTR. This leads to chloride and bicarbonate secretion from the cell, promoting excretion of sodium (Na⁺) from the basolateral cell membrane through tight junctions into the lumen and diffusion of water out of cells^[2].

How Linaclotide Works at the Molecular Level — Mechanism Highlights

What distinguishes linaclotide from conventional laxatives is its mechanism of action at the receptor and intracellular signaling level:

• High affinity GC-C receptor activation — Linaclotide binds GC-C with remarkable specificity, activating the receptor's guanylate cyclase catalytic domain. The resulting surge in cGMP serves as a second messenger to orchestrate downstream effects.
• Ion channel modulation — cGMP activates CFTR channels, increasing secretion of chloride and bicarbonate ions into the lumen. This osmotic shift draws water into the gut, softening stool and improving motility.
• Localized action and minimal systemic exposure — Pharmacokinetic studies show that linaclotide and its primary active metabolite, MM-419447, have minimal absorption into systemic circulation, confining their effects to the gastrointestinal tract and minimizing systemic side effects.

Taken together, this mechanism confers both efficacy and safety advantages, especially for chronic use in functional bowel disorders.

Figure 3. Systemic (A) and portal vein (B) concentrations of linaclotide and MM-419447 as a function of time after oral administration of linaclotide^[3].

Clinical Efficacy: What the Research and Trials Reveal

Linaclotide has been studied extensively in Phase II and III clinical trials across populations suffering from Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC). Patients treated with linaclotide demonstrated statistically significant increases in weekly spontaneous bowel movements (SBMs) and complete spontaneous bowel movements (CSBMs), coupled with reduced abdominal pain and discomfort—meeting established endpoints for regulatory approval.

Importantly, linaclotide's dual action—both pro-secretory and analgesic—addresses not only motility deficits but also the sensory disturbances that contribute to the discomfort associated with IBS-C. The expansion of extracellular cGMP is implicated in attenuating nociceptor activity, offering tangible symptomatic relief beyond simple constipation relief.

Figure 4. The efficacy of linaclotide in the treatment of IBS-C was related to its ability to modulate the gut microbiota. (A) Changes in alpha diversity indices. (B) Principal coordinate analysis (PCoA) of the gut microbiota. (C, D) The abundance of Firmicutes at the phylum level and that of Blautia at the genus level were greater after 6 weeks of treatment than at 0 weeks. (E) Linear discriminant analysis (LDA) was used to estimate the impact of the abundance of each component (genus) on the effects. (F) Community heatmap generated using color gradients to represent the size of the data in a two-dimensional matrix or table and to present community species composition information^[4].

Chemical and Physicochemical Profile — Key Data for R&D and Manufacturing

From a quality control and synthetic chemistry perspective, linaclotide's peptide nature and structure pose both opportunities and challenges:

The synthesis of linaclotide typically leverages solid-phase peptide synthesis (SPPS), enabling precise control over amino acid sequence and protecting group strategies critical for correct disulfide bridge formation. Solid-phase techniques, combined with meticulous oxidative folding, deliver the conformationally stable cyclic peptide essential for its bioactivity.

Why Alfa Chemistry Presents Linaclotide — Strategic Value for Your R&D Pipeline

At Alfa Chemistry, we understand the unique needs of pharmaceutical researchers and developers engaged in peptide therapeutic and GI disorder innovation. Our linaclotide offering is characterized by:

• High purity (>98% by HPLC), ensuring reproducibility in assay systems.
• Consistent quality control documentation, supporting analytical method development.
• Reliable supply chain, essential for both preclinical studies and formulation research.

Whether your project focuses on new gastrointestinal therapeutics, peptide formulation platforms, or GC-C receptor biology, Alfa Chemistry's linaclotide serves as a scientifically sound building block—backed by expert technical support and regulatory-compliant handling practices.

Final Thoughts: Linaclotide as a Paradigm of Targeted GI Therapeutics

Linaclotide stands at the intersection of mechanistic pharmacology, peptide science, and unmet clinical need. Its localized action, receptor selectivity, and dual functional benefits make it a valuable compound both for therapeutic application and for research into gastrointestinal physiology. We are proud to support researchers worldwide in leveraging linaclotide for innovation in GI disease treatment—transforming mechanistic insights into tangible outcomes.

Alfa Chemistry has carefully selected a number of specialty APIs of exceptional quality. Please browse the product list below to find the product you need.

Related Products & Services

Please kindly note that our services are for research use only.